List of SBIR/STTR awards granted to Salus Discovery
Salus DiscoveryName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to Salus Discovery in February, 2020 for $436,366.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44HD101201-01 | Phase I | 436,366 | February 1, 2020 | |||||||
A SBIR Phase I contract was awarded to Salus Discovery in March, 2018 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI136484-01 | Phase I | 225,000 | March 1, 2018 | |||||||
A SBIR Phase II contract was awarded to Salus Discovery in May, 2022 for $962,850.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 4R44HD101201-02 | Phase II | 962,850 | May 10, 2022 | |||||||
A SBIR Phase I contract was awarded to Salus Discovery in August, 2017 for $700,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43OD023021-01A1 | Phase I | 700,000 | August 3, 2017 | |||||||
A SBIR Phase I contract was awarded to Salus Discovery in May, 2016 for $240,747.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44GM119881-01 | Phase I | 240,747 | May 1, 2016 | |||||||
A SBIR Phase II contract was awarded to Salus Discovery in August, 2017 for $1,068,815.0 USD from the U.S. Department of Health & Human Services. | SBIR | 4R44GM119881-02 | Phase II | 1,068,815 | August 15, 2017 | |||||||
A SBIR Phase I contract was awarded to Salus Discovery for $298,743.0 USD from the U.S. Department of Health & Human Services. | SBIR | 272201600021C-0-0-0 | Phase I | 298,743 | ||||||||
A SBIR Phase I contract was awarded to Salus Discovery in April, 2023 for $275,526.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI172578-01A1 | Phase I | 275,526 | April 1, 2023 |
